Nature Communications (Oct 2020)
Globally altered epigenetic landscape and delayed osteogenic differentiation in H3.3-G34W-mutant giant cell tumor of bone
- Pavlo Lutsik,
- Annika Baude,
- Daniela Mancarella,
- Simin Öz,
- Alexander Kühn,
- Reka Toth,
- Joschka Hey,
- Umut H. Toprak,
- Jinyeong Lim,
- Viet Ha Nguyen,
- Chao Jiang,
- Anand Mayakonda,
- Mark Hartmann,
- Felix Rosemann,
- Kersten Breuer,
- Dominik Vonficht,
- Florian Grünschläger,
- Suman Lee,
- Maren Kirstin Schuhmacher,
- Denis Kusevic,
- Anna Jauch,
- Dieter Weichenhan,
- Jozef Zustin,
- Matthias Schlesner,
- Simon Haas,
- Joo Hyun Park,
- Yoon Jung Park,
- Udo Oppermann,
- Albert Jeltsch,
- Florian Haller,
- Jörg Fellenberg,
- Anders M. Lindroth,
- Christoph Plass
Affiliations
- Pavlo Lutsik
- Division of Cancer Epigenomics, German Cancer Research Center (DKFZ)
- Annika Baude
- Division of Cancer Epigenomics, German Cancer Research Center (DKFZ)
- Daniela Mancarella
- Division of Cancer Epigenomics, German Cancer Research Center (DKFZ)
- Simin Öz
- Division of Cancer Epigenomics, German Cancer Research Center (DKFZ)
- Alexander Kühn
- Division of Cancer Epigenomics, German Cancer Research Center (DKFZ)
- Reka Toth
- Division of Cancer Epigenomics, German Cancer Research Center (DKFZ)
- Joschka Hey
- Division of Cancer Epigenomics, German Cancer Research Center (DKFZ)
- Umut H. Toprak
- Bioinformatics and Omics Data Analytics, German Cancer Research Center (DKFZ)
- Jinyeong Lim
- Graduate School of Cancer Science and Policy, Cancer Biomedical Science, National Cancer Center
- Viet Ha Nguyen
- Graduate School of Cancer Science and Policy, Cancer Biomedical Science, National Cancer Center
- Chao Jiang
- Botnar Research Centre, Oxford NIHR BRC, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford
- Anand Mayakonda
- Division of Cancer Epigenomics, German Cancer Research Center (DKFZ)
- Mark Hartmann
- Section Translational Cancer Epigenomics, Division of Translational Medical Oncology, National Center for Tumor Diseases (NCT) & German Cancer Research Center (DKFZ)
- Felix Rosemann
- Division of Cancer Epigenomics, German Cancer Research Center (DKFZ)
- Kersten Breuer
- Division of Cancer Epigenomics, German Cancer Research Center (DKFZ)
- Dominik Vonficht
- Faculty of Biosciences, Ruprecht Karl University of Heidelberg
- Florian Grünschläger
- Faculty of Biosciences, Ruprecht Karl University of Heidelberg
- Suman Lee
- Graduate School of Cancer Science and Policy, Cancer Biomedical Science, National Cancer Center
- Maren Kirstin Schuhmacher
- Department of Biochemistry, Institute of Biochemistry and Technical Biochemistry, University of Stuttgart
- Denis Kusevic
- Department of Biochemistry, Institute of Biochemistry and Technical Biochemistry, University of Stuttgart
- Anna Jauch
- Institute of Human Genetics, Ruprecht Karl University of Heidelberg
- Dieter Weichenhan
- Division of Cancer Epigenomics, German Cancer Research Center (DKFZ)
- Jozef Zustin
- Institute of Pathology, University Medical Center Hamburg-Eppendorf
- Matthias Schlesner
- Bioinformatics and Omics Data Analytics, German Cancer Research Center (DKFZ)
- Simon Haas
- Division of Stem Cells and Cancer, German Cancer Research Center (DKFZ)
- Joo Hyun Park
- Department of Nutritional Science and Food Management, Ewha Womans University
- Yoon Jung Park
- Department of Nutritional Science and Food Management, Ewha Womans University
- Udo Oppermann
- Botnar Research Centre, Oxford NIHR BRC, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford
- Albert Jeltsch
- Department of Biochemistry, Institute of Biochemistry and Technical Biochemistry, University of Stuttgart
- Florian Haller
- Institute of Pathology, University Hospital Erlangen, Friedrich Alexander University Erlangen-Nürnberg
- Jörg Fellenberg
- Department of Experimental Orthopaedics, Orthopaedic University Hospital Heidelberg, Ruprecht Karl University of Heidelberg
- Anders M. Lindroth
- Graduate School of Cancer Science and Policy, Cancer Biomedical Science, National Cancer Center
- Christoph Plass
- Division of Cancer Epigenomics, German Cancer Research Center (DKFZ)
- DOI
- https://doi.org/10.1038/s41467-020-18955-y
- Journal volume & issue
-
Vol. 11,
no. 1
pp. 1 – 16
Abstract
The histone variant mutation H3.3-G34W occurs in the majority of giant cell tumor of bone (GCTB). By profiling patient-derived GCTB tumor cells, the authors show that this mutation associates with epigenetic alterations in heterochromatic and bivalent regions that contribute to an impaired osteogenic differentiation and the osteolytic phenotype of GCTB.
